PRVA Privia Health Group, Inc.
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs. Further, it offers clinical services, data analytics and day-to-day operational support through preventive health and data-driven coordination, it helps practices elevate the quality of patient care and increase patient engagement. The company was founded in 2007 and is headquartered in Arlington, Virginia.…
Industry Peers
Health Information ServicesKey Statistics
About Privia Health Group (NASDAQ: PRVA)
›
Privia Health Group (NASDAQ: PRVA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 1,226 employees.
The shares were at 25.05 USD on 20 November 2026, up 4.5% over 52 weeks. Its 52-week range is 18.92 USD to 28.82 USD: the price is 13.1% below the high and 32.4% above the low.
At a market capitalisation of 3.20B USD, it trades at 96.3 times trailing earnings and 23.5 times forward earnings. The median trailing P/E of its 15 largest Health Information Services peers is 39.9, a premium of 141% for PRVA.
Privia Health Group reports return on equity of 3.1%, an operating margin of 2.1% and revenue up 13.2% year over year.
It holds more cash than debt, a net cash position of 438.03M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 17 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 31.82 USD is 27.0% above the current price. The next earnings report is expected on 25 February 2027.